Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3211 - Phase 1b/2 study to evaluate the safety, tolerability and pharmacokinetics of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer and FGFR mRNA overexpression

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Tumour Site

Urothelial Cancer

Presenters

Jonathan Rosenberg

Citation

Annals of Oncology (2018) 29 (suppl_8): viii303-viii331. 10.1093/annonc/mdy283

Authors

J. Rosenberg1, A. Necchi2, R.F. Sweis3, K. Nakajima4, C. Lu5, H. Nogai6

Author affiliations

  • 1 Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 2 Medical Oncology, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, 20133 - Milan/IT
  • 3 Section Of Hematology/oncology - Department Of Medicine, University of Chicago, Chicago/US
  • 4 Clinical Development, Bayer HealthCare Pharmaceuticals, Whippany/US
  • 5 Clinical Statistics, Bayer HealthCare Pharmaceuticals, Whippany/US
  • 6 Oncology, Bayer AG, 13353 - Berlin/DE

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3211

Background

PD-(L)1 inhibitors have been shown to be effective in patients with metastatic urothelial cancer (UC) who are ineligible to receive cisplatin-based chemotherapy, with the PD-L1 inhibitor atezolizumab being FDA-approved. Dysregulation of fibroblast growth factor receptors (FGFR) has been shown to play a role in UC development and progression, and FGFR3 overexpression/molecular alterations are associated with a non-T-cell inflamed tumor microenvironment. Rogaratinib, an oral pan-FGFR 1-4 inhibitor, has shown promising efficacy in a phase I study in UC patients selected based on FGFR1-3 overexpression, including patients who rapidly progressed on immunotherapy. The aim of this study is to explore the clinical safety and benefit of combining rogaratinib with atezolizumab.

Trial design

This is a multicenter, phase 1b/2 study of rogaratinib in combination with atezolizumab in patients with FGFR-positive locally advanced or metastatic UC. The primary objectives of the single-arm phase 1b portion are to determine the safety, tolerability, recommended phase-2 dose (RP2D) and pharmacokinetics of rogaratinib in combination with atezolizumab. The primary objective of the randomized phase 2 portion is to compare progression-free survival (PFS) of rogaratinib plus atezolizumab versus placebo plus atezolizumab in chemotherapy-untreated patients with FGFR-positive locally advanced or metastatic UC. Patients will be tested for FGFR1/3 mRNA expression levels in archival tumor samples (RNAscope®) and patients with FGFR-positive UC will enter into screening, regardless of the presence of FGFR mutations or translocations. Eligible patients will be treated with a starting dose of daily rogaratinib 800 mg po bid together with a fixed dose of 1200 mg atezolizumab iv on day 1 of a 21-day cycle. Following determination of the RP2D, patients will be randomized 1:1 to rogaratinib plus atezolizumab versus placebo plus atezolizumab. The primary efficacy variable is PFS based on assessment of blinded independent central review. Approximately 160 patients will be enrolled.

Clinical trial identification

NCT03473756.

Legal entity responsible for the study

Bayer AG.

Funding

Bayer AG.

Editorial Acknowledgement

Disclosure

K. Nakajima, C. Lu, H. Nogai: Employee: Bayer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.